SCHEMBL4693972

SCHEMBL4693972

Nc1cncc(-c2ccncc2Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
CDK2 P24941 1/20 0.44
IDO1 P14902 1/20 0.41
LATS1 O95835 5/20 0.40
PRKCH P24723 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCD Q05655 1/20 0.39
NFATC1 O95644 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
PIM1 P11309 1/20 0.39
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
LIMK1 P53667 1/20 0.37
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27715330 0.84 CCNC (0.41) GAACDK2IDO1LATS1PRKCH
SCHEMBL3362503 0.80 HSP90AA1 (0.50) CDK2IDO1PIM1PIM3PIM2
SCHEMBL23246118 0.74 IDO1 (0.47) CDK2IDO1ALOX5APFEN1
SCHEMBL31301252 0.73 GSK3B (0.59) GAACDK2IDO1LATS1NFATC1
SCHEMBL3942126 0.72 HSP90AA1 (0.63) GAAIDO1LATS1PRKCHPRKCE
SCHEMBL3063403 0.72 GAA (0.44) GAACDK2IDO1LATS1NFATC1
SCHEMBL23143338 0.71 LMNA (0.42) GAACDK2IDO1PRKCHPRKCE
SCHEMBL10955121 0.70 GAA (0.46) GAAIDO1PRKCHPRKCEPRKCQ
SCHEMBL4694199 0.70 GAA (0.42) GAAIDO1LATS1NFATC1GSK3B
SCHEMBL23348877 0.70 LATS1 (0.51) GAACDK2IDO1LATS1NFATC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 GAA 1332/4885CDK2 2015/4885IDO1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.